What is Inventiva?
Headquartered in France, Inventiva operates at the intersection of advanced molecular biology and clinical medicine. The firm distinguishes itself through a focused approach to developing innovative treatments for complex pathologies. By targeting specific biological pathways, Inventiva aims to deliver transformative outcomes for patients suffering from chronic and life-threatening conditions. Its market position is bolstered by a disciplined R&D strategy and a history of attracting top-tier life sciences investors who prioritize long-term value creation in the biopharmaceutical sector.
How much funding has Inventiva raised?
Inventiva has raised a total of $542.6M across 6 funding rounds:
Other Financing Round
$16.4M
Stock Offering
$107.7M
Share Placement
$36.7M
Private Equity
$99.6M
Debt
$131M
Debt
$151.2M
Other Financing Round (2020): $16.4M with participation from Novo Holdings, NEA, Sofinnova Partners, and BVF Partners L.P.
Stock Issuance/Offering (2020): $107.7M, investors not publicly disclosed
Share Placement (2023): $36.7M, investors not publicly disclosed
Private Equity (2024): $99.6M featuring New Enterprise Associates, Samsara BioCapital, and BVF Partners
Debt (2025): $131M, investors not publicly disclosed
Debt (2026): $151.2M with participation from BlackRock and Claret Capital Partners
Key Investors in Inventiva
Novo Holdings
Novo Holdings is a Danish private limited liability company wholly owned by the Novo Nordisk Foundation, focusing on long-term value creation in the life sciences sector.
Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability with a hands-on approach to company building.
BlackRock
BlackRock is a global investment management firm providing comprehensive financial services and risk management to institutional and individual clients worldwide.
What's next for Inventiva?
Looking ahead, the deployment of this capital will be pivotal for Inventiva as it navigates the complexities of late-stage clinical development. The strategic focus will likely remain on optimizing its lead assets while maintaining operational agility in a competitive global landscape. With the support of its diverse investor base, the company is poised to strengthen its intellectual property portfolio and potentially forge new collaborative partnerships. The emphasis will be on achieving key clinical milestones that validate the efficacy of its therapeutic platform, thereby enhancing its long-term enterprise value and market standing.
See full Inventiva company page
